[Experimental evaluation of cisplatin analogous in urogenital cancer].
We studied the efficiency and toxicity of three types of recently developed cisplatin analogous agents-carboplatin, 254-S and DW2114, in animal experiments and clinical examinations. In animal experiments, these three agents were injected into SD rats intraperitoneally to determine their effects on rat functions. The antitumor effect of these agents was about the same as that of CDDP, but the renal toxicity of 254-S and DW2114 was lower than that of CDDP. However, more serious myelopathy was observed with these agents than with CDDP. Although slight damage to the testis was seen in the 254-S group, damage to the testis by the other agents was negligible. It was suggested that the damaged region in the testis was spermatogonia. In clinical examinations, we administered the three analogous agents separately for testicular tumors, prostatic cancer and bladder tumors, but a complete response (5M) was recognized in only one case given 245-S, and we found these three agents less effective than CDDP. At present, CDDP is extensively used clinically as one of the combination therapy agents. However, in the first place, we should develop a new CDDP analogous agent that has an anti-tumor effect greater than that of CDDP.